Efficacy News and Research

RSS

First long-acting injectable HIV treatment appraised and approved by NICE

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

19 Nov 2021

Can you take the COVID-19 and Influenza vaccines on the same day?

Scientists have conducted a substudy within a phase 3 UK trial and have reported the safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with licensed seasonal influenza vaccines.

19 Nov 2021

UCLA study shows how COVID vaccination is critical to controlling the pandemic

A study currently available on the medRxiv* preprint server has demonstrated that the incidence and mortality rates of coronavirus disease 2019 (COVID-19) in the US can be significantly reduced at the population level by increasing vaccinate rates from 40% to 80%.

18 Nov 2021

A nasal COVID vaccine using a weakened influenza vector

The authors of a new study, published on the bioRxiv* preprint server, constructed a COVID-19 nasal vaccine candidate by inserting a gene encoding the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2, named CA4-dNS1-nCoV-RBD (dNS1-RBD) in a live attenuated influenza virus (LAIV) vector.

18 Nov 2021

Air filter and floor sampling to detect SARS-CoV-2 RNA in schools

A study recently published on the medRxiv* preprint server observed the presence of SARS-CoV-2 RNA in five schools (96 classrooms) in Davis, California (USA), by collecting weekly surface-swab samples from classroom floors and/or portable high-efficiency particulate air (HEPA) units.

18 Nov 2021

New trial demonstrates stable coagulation factor VIII in hemophilia A patients after gene therapy

A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete elimination – of painful and potentially life-threatening bleeding events, according to a new study led by researchers at Children's Hospital of Philadelphia.

18 Nov 2021

REGEN-COV is effective in preventing severe COVID-19 in immunocompromised individuals

A recent study assesses the efficacy of repeat doses of REGEN-COV in SARS-CoV-2-negative adults who were healthy or had chronic medical conditions.

18 Nov 2021

NIH study finds naturally acquired immunity is weak against SARS-CoV-2 variants

Immunity acquired after recovering from SARS-CoV-2 infection is not sufficient in protecting against reinfection from variants.

18 Nov 2021

Simulating SARS-CoV-2 transmission dynamics for reopening European universities

Researchers from Graz University of Technology modeled transmission dynamics in a European university.

18 Nov 2021

Short-term severe calorie restriction safe, feasible, and well tolerated by cancer patients

A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood glucose and growth factor concentration, reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration in cancer patients receiving standard-of-care therapy, according to the results of a clinical trial.

18 Nov 2021

The antiviral function of BET protein against SARS-CoV-2 infection

Considering the past shreds of evidence on BRD2 and BRD4 associated with viral infections, researchers have recently evaluated the function of all relevant BET proteins during COVID-19 infection.

17 Nov 2021

Vaccines and boosters remain strong against current SARS-CoV-2 variants

In a recent study published in the Lancet Microbe journal, Australian researchers studied whether in-vitro neutralization titers could predict vaccine protection from SARS-CoV-2 variants.

17 Nov 2021

Long-term Pfizer vaccine-elicited SARS-CoV-2 antibody profile in breast milk

A new study indicates that the Pfizer vaccine induces antibodies in the breast milk against SARS-CoV-2.

17 Nov 2021

Efficacy of UVC light prototype devices for inactivating SARS-CoV-2

Researchers examined the efficacy of UVC light prototype devices to understand the duration and wavelength of UVC radiation needed for SARS-CoV-2 inactivation.

17 Nov 2021

New technology could revolutionize treatment of pediatric burns

Burns are one of the most common injuries suffered by Australians and one of the top causes of death in children under four. While survival rates for burns patients have improved substantially, treating paediatric burns remains challenging, especially with the rise of multi-drug resistant bacteria.

17 Nov 2021

Nationwide Swedish study strengthens evidence for a third booster COVID vaccine dose

A nationwide study from Sweden investigates the effectiveness of COVID-19 vaccination against the risk of symptomatic infection, hospitalization, and death up to 9 months post-vaccination. This study is published on the Preprints with The Lancet website while awaiting peer review.

17 Nov 2021